Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Stock Snapshot

IR Contacts

Headquarters

Sutro Biopharma, Inc.
111 Oyster Point Blvd
South San Francisco, CA 94080

Investor Relations

Sutro Biopharma
Emily White
Executive Director, Investor Relations and Communications
T: 650-823-7681
ewhite@sutrobio.com